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Abstract
Purpose: The purpose of this study was to describe the biological behaviour of mucinous breast carcinoma (MBC) 
regarding their clinical presentations, pathological features, prognosis and survival.
Methodology: We conducted this retrospective study from 2006 to 2015 (10-year duration) and included all the 
patients who presented with mucinous carcinoma of the breast at any age. We excluded all the patients who presented 
with invasive ductal carcinoma or other rare breast tumours. Each patient with mucinous carcinoma breast was 
categorised in terms of diagnosis, surgery, chemotherapy and outcome. For categorical variables, Chi-square test was 
used. Kaplan–Meier curves were used to determine estimated overall survival. Data analysis was carried out using the 
SPSS 20.
Results: In total, 8841 patients with breast carcinoma presented during the study period. Of these, 74 patients 
were diagnosed as cases of MBC, constituting <1%. Family history of breast carcinoma was positive in 20% of 
patients. Most of the women were postmenopausal (66.2%) falling in BIRADS Category 4 and 5 (32.4% each). 
Considering laterality tumours had almost equal distribution between the right and left side. Breast-conserving 
surgery was performed in 47.3% of women as compare to modified radicle mastectomy in 52.7% of women. Most 
of the patients had pathological T2 (51.4%), N0 (81.1%) and moderately differentiated (69%) mucinous carcinoma. 
ER was positive in 85% of patients, PR in 80% and H2N in 74.6% of patients. Neoadjuvant chemotherapy was 
given to 20 patients (27%) and adjuvant chemoradiotherapy was given to 51 patients (69%). Metastasis occurred 
in 12 (16.2%) of our patients while 62 (83.8%) were metastasis free on long-term follow-up, with bones being the 
most common site of metastasis, occurring in 6 patients (8.1%) followed by lungs, occurring in 4 patients (5.4%). 
A total of 32 (43.2%) patients are alive, and on regular follow-up, 3 (4.1%) died during the course of follow-up 
and 39 (52.7%) are lost to follow-up with a median survival of 60 months and an overall 5-year survival rate of 
>95%.
Conclusion: Mucinous carcinoma is a rare breast carcinoma with a good prognosis.
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Introduction
Mucinous carcinoma of breast is one of the rare breast 
tumours, having an incidence of 1–6% amongst all types 
of the primary carcinomas of breast.[1] Mucinous breast 
carcinoma (MBC), sometimes called colloid carcinoma, 
is a type of invasive ductal cancer.
According to the current General Rules for Clinical and 
Pathological Recording of Breast Cancer, mucinous 
neoplasms are defined as the ones where a certain type 
of cell able to produce mucus, makes the major bulk of 
tumour.[2] The neoplasm is actually composed of islands 
of tumour cells floating in lakes of extracellular mucin. 
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The prevalence of MBC is more in women over 60 years 
of age.[3] MBC is considered to be a favourable diagnosis 
because it has lower metastatic nodal involvement 
incidence,[4] better histological differentiation and 
a higher expression of oestrogen and progesterone 
receptors.[5,6] MBC is divided into pure (PMBC) and 
mixed (MMBC) subtype. The basis of this classification 
is on the quantification of tumour cellularity. A tumour 
with >50% of mucinous component is regarded as a 
mucinous neoplasm.[7] However, clear-cut criteria for 
differentiation between a pure and a mixed subtype of 
MBC have not yet been defined.[8-10] Mixed types of 
ductal carcinomas with both mucinous and non-mucinous 
components (incidence of 2%) need to be differentiated 
from PMBC as they have prognosis identical to their non-
mucinous components.[11,12] Short-term survival has been 
documented to be superior in pure mucinous subtype as 
compared to their mixed counterparts.[13] However, long-
term survival is reported to be similar and the prognosis 
even tends to go downhill on longer follow-up.[14,15] Some 
researchers claim that the recurrence rates in mucinous 
cancers are identical to invasive ductal carcinoma 
after 10–15 years of follow-up.[16-18] In the present 
study, we did a retrospective analysis of patients with 
MBC to describe the biological behaviour of MBC 
regarding their clinical presentations, pathological 
features and prognosis. We also discuss the surgical and 
chemotherapeutic treatments that patients received and 
compare their affectivity.
Methodology
We conducted this retrospective study at Shaukat Khanum 
Memorial Cancer Hospital and Research Centre from 2006 
to 2015 (10-year duration) and included all the patients 
who presented with mucinous carcinoma of the breast at 
any age. We excluded all the patients who presented with 
invasive ductal carcinoma or other rare breast tumours. 
Hospital records of all the patients with mucinous 
carcinoma breast were analysed. A set of parameters 
were defined to record initial clinical presentation and 
examination, imaging and laboratory findings. A decision 
of multidisciplinary team meetings, surgical treatment, 
neoadjuvant, post-operative chemotherapy and radiation 
data was retrieved. Each patient with mucinous carcinoma 
breast was categorised in terms of diagnosis, surgery, 
chemotherapy and outcome. For categorical variables, 
Chi-square test was used. Overall survival was calculated 
by subtracting date of the last follow-up from date of 
surgery in the hospital. Kaplan–Meier curves were used to 
determine estimated overall survival and Cox regression 
analysis was performed to determine the significance of 
individual variable. All analyses were performed on the 
SPSS version 20.
Results
A total of 74 patients presented to our hospital during the 
study period with MBC with a median age of 57 years 
(standard deviation ± 14.5). Family history of breast 
carcinoma was positive in 20% of patients. Most of the 
women were postmenopausal (66.2%) falling in BIRADS 
Category 4 and 5 which are 32.4% each. Tumours were 
almost equally distributed between the right and left side. 
Breast-conserving surgery was performed in 47.3% of 
women as compared to modified radicle mastectomy in 
52.7% of women as shown in Table 1.
Table 1: Patient characteristics











Category 0 10 (13.5)
Category 1 1 (1.4)
Category 2 4 (5.4)
Category 3 4 (5.4)
Category 4 24 (32.4)
Category 5 24 (32.4)
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Most of the patients were having pathological T2 (51.4%) 
followed by T1 (43.5%). 81.1% of patients had no 
nodal disease at presentation. Moderately differentiated 
mucinous carcinoma was most common (69%). ER was 
positive in 85% of patients, PR in 80% and H2N in 74.6% 
of patients. Neoadjuvant chemotherapy was given to 
20 patients (27%) and adjuvant chemoradiotherapy was 
given to 51 patients (69%) as shown in Table 2. On long-
term follow-up, metastasis occurred in 12 (16.2%) of 
our patients while 62 (83.8%) were metastasis free, with 
bones being the most common site of metastasis, occurring 
in 6 patients (8.1%) followed by lungs, occurring in 
4 patients (5.4%). A total of 32 (43.2%) patients are alive, 
and on regular follow-up, 3 (4.1%) died during the course 
of follow-up and 39 (52.7%) were lost to follow-up with 
a median survival of 60 months and an overall 5-year 
survival rate of >95%.
Discussion
In the past 10 years from 2006 to 2015, the total number 
of patients diagnosed with breast cancer at our institution 
was 8841. Of these, only 74 patients were diagnosed with 
MBC constituting <1% of total patients, which is similar 
to what has been reported in literature.[1,2] Furthermore, 
the frequency might be lower in our population because 
we are dealing with unscreened population. Most patients 
were of old age with a median age of 57 years. This is also 
similar to what has been reported in literature. The average 
age of occurrence for this tumour is >60 years.[3] Most of 
the patients (66.2%) were postmenopausal as compared 
to 33.8% presented in premenopausal age group.
Most of the tumours presented to us were either T1 
or T2. This is explained by the fact that mucinous 
tumours are slow-growing tumours with a very low 
metastatic potential. Our patients had no metastasis at 
presentation. Surgical options for these patients included 
both mastectomies and breast conservation. Due to low 
metastatic potential, these tumours can grow to large sizes 
without any evidence of metastasis. This is one reason that 
most of these patients underwent mastectomies due to the 
large size of the tumours. Neoadjuvant therapy was offered 
to 27% of patients. These tumours have been shown to 
have a high expression of hormone receptors.[11,12] 85% 
of our patients were ER positive, 80% were PR positive 
and 74% were H2N positive. Due to high percentage 
of hormone receptor expression, these tumours show 
good response to adjuvant endocrine and chemotherapy. 
Adjuvant therapy was offered to 69% of our patients.[12-15]
Mucinous breast cancer is associated with low rates 
of local and distant recurrence and outstanding 5-year 
disease-free survival rates both in literature and in our 
series. A large retrospective comparative study showed 
that PMC of the breast had less aggressive behaviour 
compared to infiltrative ductal carcinoma, and the 
favourable outcome still remained after 20 years[13]. In 
Table 2: Disease stage and treatment











Well differentiated 13 (17.5)
Moderately differentiated 51 (69.0)
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our series, only 12 patients developed metastasis. There 
were only 3 deaths (4%). All other patients were alive at 
5-year follow-up.
 Limitations of our study include, as it is a retrospective 
data, most of our patients are lost to follow-up. The reason 
for that is the fact that these patients mostly belong to far-
flung area, have long travelling distances and complete 
lack of education and finances. Yet, this is the first attempt 
at reporting a large data from any of the centres from 
Pakistan. Based on this data, we intend to prospectively 
include parameters of assessment, which will enable us, 
to improve our results as well as data set will be much 
stronger.
Conclusion
MBC of the breast has a favourable prognosis. It has low 
rates of metastasis with a very good 5-year survival rates.
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